Kales A, Bixler E O, Soldatos C R, Mitsky D J, Kales J D
J Clin Pharmacol. 1982 Nov-Dec;22(11-12):520-30. doi: 10.1002/j.1552-4604.1982.tb02645.x.
Lormetazepam, an investigational hypnotic, was evaluated for efficacy and withdrawal phenomena in doses of 0.5, 1.0, 1.5, and 2.0 mg in four separate sleep laboratory protocols, each including four placebo baseline nights, seven drug nights, and three placebo withdrawal nights. A moderate degree of efficacy was shown across the four doses, but this was quite variable. There was no dose-response effect for efficacy for either the first three or last three nights of this short-term administration period. In general, there was less efficacy on the later drug nights, indicating a potential for the development of tolerance over a relatively short period of time. Following drug withdrawal, there was a dose-related worsening of sleep above baseline levels (rebound insomnia). The peak degree of worsening of sleep following drug withdrawal was more than two times greater than the peak degree of improvement of sleep with drug administration.
氯美扎酮是一种正在研究的催眠药，在四个独立的睡眠实验室方案中，分别以0.5毫克、1.0毫克、1.5毫克和2.0毫克的剂量对其疗效和撤药现象进行了评估，每个方案包括四个安慰剂基线夜、七个用药夜和三个安慰剂撤药夜。在这四个剂量下均显示出中等程度的疗效，但差异较大。在这个短期给药期的前三个晚上或最后三个晚上，疗效均无剂量反应效应。一般来说，在后续用药夜的疗效较低，表明在相对较短的时间内有产生耐受性的可能。撤药后，睡眠恶化程度与剂量相关，高于基线水平（反弹性失眠）。撤药后睡眠恶化的峰值程度比用药时睡眠改善的峰值程度高出两倍多。
